Detalhe da pesquisa
1.
REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.
Br J Haematol
; 168(6): 796-805, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25403830
2.
A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia.
Haematologica
; 100(2): 231-7, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25381131
3.
Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study.
Am J Hematol
; 94(4): E90-E93, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30592080
4.
Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial.
JAMA Oncol
; 7(9): 1343-1350, 2021 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34236401
5.
A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors.
Clin Cancer Res
; 14(7): 2075-81, 2008 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18381947
6.
Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies.
Clin Cancer Res
; 25(4): 1174-1184, 2019 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30333224
7.
A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
Clin Cancer Res
; 12(23): 7046-53, 2006 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17145827
8.
Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer.
J Clin Oncol
; 32(14): 1437-44, 2014 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-24733796
9.
Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer.
J Thorac Oncol
; 6(2): 384-6, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21252718